116 related articles for article (PubMed ID: 31904566)
1. Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial.
Wei LH; Su YY; Hu YM; Li RC; Chen W; Pan QJ; Zhang X; Zhao FH; Zhao YQ; Li Q; Hong Y; Zhao C; Li MQ; Liu WY; Li CH; Guo DP; Ke LD; Lin BZ; Lin ZJ; Chen S; Sheng W; Zheng ZZ; Zhuang SJ; Zhu FC; Pan HR; Li YM; Huang SJ; Zhang J; Qiao YL; Wu T; Xia NS
Clin Microbiol Infect; 2020 Aug; 26(8):1069-1075. PubMed ID: 31904566
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
[TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women.
Ji J; Sun HK; Smith JS; Wang H; Esser MT; Hu S; Pretorius RG; Chen W; Belinson JL; Qiao YL
BMC Infect Dis; 2012 Jun; 12():137. PubMed ID: 22715915
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
[TBL] [Abstract][Full Text] [Related]
5. [Detection of neutralizing antibodies and DNA of human papillomavirus 16, 18 in women aged 18-45 years in Funing, Jiangsu province].
Liu W; Wei F; Tang J; Yang S; Gao Y; Wang T; Jiang Y; Li M; Hong Y; Chu K; Chen W; Hu Y; Zhu F
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Mar; 37(3):406-9. PubMed ID: 27005547
[TBL] [Abstract][Full Text] [Related]
6. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
[TBL] [Abstract][Full Text] [Related]
8. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
Hildesheim A; Herrero R; Wacholder S; Rodriguez AC; Solomon D; Bratti MC; Schiller JT; Gonzalez P; Dubin G; Porras C; Jimenez SE; Lowy DR;
JAMA; 2007 Aug; 298(7):743-53. PubMed ID: 17699008
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of human papillomavirus 16 and 18 neutralizing antibodies in prenatal women in British Columbia.
Krajden M; Karunakaran K; So S; Palefsky JM; Sharma R; Cook D; Yu A; Chow R; Dobson S; Ogilvie GS; Petric M
Clin Vaccine Immunol; 2009 Dec; 16(12):1840-3. PubMed ID: 19828766
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors for neutralizing antibodies to human papillomavirus types 16 and 18 in HIV-positive men who have sex with men.
Sharma R; Efird JT; Chein A; Holly EA; Krajden M; Berry JM; Darragh TM; Jay N; Palefsky JM
J Acquir Immune Defic Syndr; 2013 Dec; 64(5):479-87. PubMed ID: 24231786
[TBL] [Abstract][Full Text] [Related]
12. [Distribution of serum antibodies against human papillomavirus 16 and 18 among high-risk women to cervical cancer].
Fei M; Li J; Du J; You J; Zhang S; He W; Kang L; Zhao F; Qiao Y; Si Y; Fan X; Chen W
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 May; 35(5):514-8. PubMed ID: 25059358
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
17. Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies.
Rosillon D; Baril L; Del Rosario-Raymundo MR; Wheeler CM; Skinner SR; Garland SM; Salmeron J; Lazcano-Ponce E; Vallejos CS; Stoney T; Ter Harmsel B; Lim TYK; Quek SC; Minkina G; McNeil SA; Bouchard C; Fong KL; Money D; Ilancheran A; Savicheva A; Cruickshank M; Chatterjee A; Fiander A; Martens M; Bozonnat MC; Struyf F; Dubin G; Castellsagué X
Cancer Med; 2019 Aug; 8(10):4938-4953. PubMed ID: 31273942
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
19. Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young norwegian women.
Kim S; Arduino JM; Roberts CC; Marsico M; Liaw KL; Skjeldestad FE
Sex Transm Dis; 2011 Jul; 38(7):587-97. PubMed ID: 21301390
[TBL] [Abstract][Full Text] [Related]
20. Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China.
Nie J; Liu J; Xie H; Sun Z; Zhao J; Chen Q; Liu Y; Huang W; Ruan Q; Wang Y
J Med Virol; 2016 Nov; 88(11):1989-98. PubMed ID: 27061569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
